New positive study results presented for Dymista
Meda presents new positive results from a Phase-III clinical trial of Dymista (also known as MP29-02) at the annual meeting of the European Academy of Allergy and Clinical Immunology (EAACI) in Istanbul, Turkey (11–15th June 2011)1-5. By 2015, half of all Europeans will suffer from an allergy according to the European Federation of Allergy and Airway Diseases6. Allergic rhinitis (AR) has become a challenge to treat, mainly due to an increase in the prevalence of severe allergic rhinitis over the last decade. Currently, 500 million people around the world suffer from AR with approximately